Disopyramide: Six Years' Experience

Wilson, Richard R.; Wallace, Andrew G.
June 1983
Angiology;Jun1983, Vol. 34 Issue 6, p367
Academic Journal
Since its approval by the FDA six years ago, oral disopyramide has earned a recognized role in the treatment of ventricular arrhythmias. During this time, clinical experience has refined our knowledge of this agent, allowing revision of dosing guidelines and better selection of patients. This review explores the recent therapeutic experience with disopyramide.


Related Articles

  • Risk Factors for Tachycardia Events Caused by Antiarrhythmic Drugs: Experience From the ESVEM Trial. Sharma, Param P.; Ott, Peter; Hartz, Vernon; Mason, Jay W.; Marcus, Frank I. // Journal of Cardiovascular Pharmacology & Therapeutics;Dec1998, Vol. 3 Issue 4, p269 

    The article presents a clinical analysis wherein scientists report that the use of antiarrhythmic drugs has adverse effects including ventricular proarrhythmia. Studies show that by testing patients treated with antiarrhythmic drugs through the ESVEM trial, scientists were able to detect the...

  • 01. Lambeth Conventions update: the agenda. Curtis, M. J. // Heart;Jan2011, Vol. 97 Issue 1, pe1 

    The advances made in pharmacotherapy of cardiac arrhythmias in the last 20⇔…years have been disappointingly meagre. The Lambeth Conventions (Walker et al, 1988) is a guidance for (ventricular) arrhythmia research. It was published more than 20⇔…years ago. It has...

  • The Clinical Scope of Disopyramide Seven Years After Introduction -- An Overview. Willis III, Park W. // Angiology;Feb1987 Part 2, Vol. 38, p165 

    Disopyramide phosphate, seven years after its introduction, has proved to be a useful and effective Type IA oral agent for treatment of ventricular arrhythmias. The experience of these seven years has amplified and more sharply defined the initial efficiency and safety issues related to the use...

  • Disopyramide Plasma Concentrations Following Single and Multiple Doses of the Immediate- and Controlled-Release Capsules. Karim, Aziz; Schubert, Elliot N.; Burns, Thomas S.; Palmer, Michael; Zinny, M. A. // Angiology;Jun1983, Vol. 34 Issue 6, p375 

    The article discusses disopyramide plasma concentrations following single and multiple doses of the immediate- and controlled-release capsules. Disopyramide phosphate is a type 1 antiarrhythmic drug used for suppression and prevention of recurrence of specific cardiac arrhythmias. It is freely...

  • A Randomized, Double-Blind, Parallel Group Comparison of Disopyramide Phosphate and Quinidine in Patients with Cardiac Arrhythmias. Arif, Mohammed; Laidlaw, James C.; Oshrain, Carl; Willis III, Park W.; Nissen, Catherine H.; McDermott, Daniel J.; Smith, W. Scott; Karim, Aziz; Wilson, Richard R. // Angiology;Jun1983, Vol. 34 Issue 6, p393 

    This report summarizes the results of a randomized, double-blind, parallel group, multicenter study which compared the antiarrhythmic activity and safety of oral disopyramide phosphate and oral quinidine sulfate. A total of 124 outpatients, whose pretreatment rates of ventricular and/or...

  • EVALUATION OF A NEW QUINIDINE COMPOUND: A COMPARATIVE STUDY. Pote, Harry H. // Angiology;Jul1961, Vol. 12 Issue 7, p320 

    Twenty-five patients with various cardiac arrhythmias were treated with a new quinidine salt, quinidine polygalacturonate. The usual daily dosage was one 275-mg tablet. Duration of therapy averaged 133 days In 50 per cent of the patients, quinidine polygalacturonate provided more satisfactory...

  • Preface [Hot topic: Anti-arrhythmic Drugs (Guest Editors: Uwe Gerlach & Heinrich C. Englert)]. Gerlach, Uwe; Englert, Heinrich C. // Current Medicinal Chemistry - Cardiovascular & Hematological Age;Oct2003, Vol. 1 Issue 3, p1 

    Arrhythmias are considered to be an important risk factor, which significantly contributes to mortality and morbidity of cardiovascular patients. However, presently available antiarrhythmic drugs are not generally accepted as a means for risk reduction, mainly due to proarrhythmic side effects...

  • Maternal arrhythmias during pregnancy. Ferrero, Simone; Colombo, Barbara Maria; Ragni, Nicola // Archives of Gynecology & Obstetrics;May2004, Vol. 269 Issue 4, p244 

    Introduction.. An increased incidence of maternal cardiac arrhythmias is observed during pregnancy and they can range from clinically irrelevant isolated premature beats to debilitating supraventricular and ventricular tachycardias. Discussion.. Management of arrhythmias during pregnancy is...

  • Antimicrobial-Associated QT Interval Prolongation: Pointes of Interest. Owens, Jr., Robert C.; Nolin, Thomas D. // Clinical Infectious Diseases;12/15/2006, Vol. 43 Issue 12, p1603 

    Until recently, cardiac toxicity manifesting in the form of arrhythmias related to QT interval prolongation was uncommonly appreciated within the antimicrobial class of drugs, but it was well described among antiarrhythmic agents. Antimicrobials that are associated with QT prolongation include...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics